Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M485Revenue (TTM) $M107Net Margin (%)-75.3Altman Z-Score-4.0
Enterprise Value $M479EPS (TTM) $-0.6Operating Margin %-76.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score8.7Pre-tax Margin (%)-75.3Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.2Cash flow > EarningsN
Price/Sales4.55-y EBITDA Growth Rate %--Current Ratio3.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-40.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-373.1Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M143ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with ARRY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARRYKen Fisher 2015-09-30 Buy $4.56 - $7.11
($5.94)
$ 3.38-43%New holding135,695
ARRYFirst Eagle Investment 2011-12-31 Sold Out -0.0024%$1.77 - $2.83
($2.27)
$ 3.3849%Sold Out0
ARRYGeorge Soros 2011-12-31 Sold Out -0.0008%$1.77 - $2.83
($2.28)
$ 3.3848%Sold Out0
ARRYGeorge Soros 2011-09-30 Buy $1.99 - $2.62
($2.24)
$ 3.3851%New holding22,400
ARRYFirst Eagle Investment 2011-06-30 Add$2.06 - $3.21
($2.7)
$ 3.3825%Add 150.00%250,000
ARRYGeorge Soros 2011-06-30 Sold Out $2.06 - $3.21
($2.7)
$ 3.3825%Sold Out0
ARRYFirst Eagle Investment 2011-03-31 Buy $2.7 - $3.29
($3)
$ 3.3813%New holding100,000
ARRYGeorge Soros 2011-03-31 Buy $2.7 - $3.29
($3)
$ 3.3813%New holding14,400
ARRYFirst Eagle Investment 2010-09-30 Sold Out -0.01%$2.67 - $3.44
($3.02)
$ 3.3812%Sold Out0
ARRYFirst Eagle Investment 2010-06-30 Reduce-0.01%$2.66 - $4.02
($3.41)
$ 3.38-1%Reduce -54.96%450,000
ARRYFirst Eagle Investment 2009-12-31 Add0.01%$1.72 - $2.81
($2.2)
$ 3.3854%Add 62.96%999,132
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARRY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARRY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Redmile Group, LLC10% Owner 2016-01-20Buy300,000$3.195.96view
Redmile Group, LLC10% Owner 2016-01-12Buy75,000$3.6-6.11view
Redmile Group, LLC10% Owner 2016-01-11Buy925,000$3.67-7.9view
Redmile Group, LLC10% Owner 2015-10-01Buy782,592$4.58-26.2view
Redmile Group, LLC10% Owner 2015-10-01Buy600,140$4.58-26.2view
Redmile Group, LLC10% Owner 2015-08-26Buy49,900$5.48-38.32view
Redmile Group, LLC10% Owner 2015-08-25Buy790,000$5.38-37.17view
Redmile Group, LLC10% Owner 2015-08-12Buy532,500$5.88-42.52view
Redmile Group, LLC10% Owner 2015-08-10Buy1,048,993$5.8-41.72view
BAUM CHARLES MDirector 2015-05-08Sell25,000$7.38-54.2view

Quarterly/Annual Reports about ARRY:

News about ARRY:

Articles On GuruFocus.com
Screen: Stocks With Estimated Revenue Up 5% - January Jan 18 2016 
Insider Buys Round-up: Tenet Healthcare and Sprint Corp Aug 14 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 

More From Other Websites
Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : May 23,... May 23 2016
Array BioPharma Announces Key Data from NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO... May 18 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 18 2016
Array BioPharma Announces Key Data from NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO... May 18 2016
ARRAY BIOPHARMA INC Financials May 12 2016
Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : May 9, 2016 May 09 2016
Array BioPharma To Present At The Bank of America Merrill Lynch HealthCare Conference May 05 2016
Array BioPharma To Present At The Bank of America Merrill Lynch HealthCare Conference May 05 2016
ARRAY BIOPHARMA INC Files SEC form 10-Q, Quarterly Report May 04 2016
Edited Transcript of ARRY earnings conference call or presentation 4-May-15 1:00pm GMT May 04 2016
Edited Transcript of ARRY earnings conference call or presentation 3-May-16 1:00pm GMT May 03 2016
Array Biopharma Inc Earnings Call scheduled for 9:00 am ET today May 03 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 03 2016
Array BioPharma reports 3Q loss May 03 2016
Array BioPharma reports 3Q loss May 03 2016
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2016 May 03 2016
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2016 May 03 2016
Q3 2016 Array Biopharma Inc Earnings Release - Before Market Open May 03 2016
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2016 On May 3, 2016 Apr 26 2016
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2016 On May 3, 2016 Apr 26 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)